一分钟看懂
这是一项关于多发性骨髓瘤的III 期研究，登记的药物或干预包括Teclistamab；Daratumumab；Lenalidomide；Dexamethasone；Talquetamab，当前状态为招募中。登记地点显示中国北京、长春、长沙、常州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Teclistamab；Daratumumab；Lenalidomide；Dexamethasone；Talquetamab · III 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出5项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出6项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking Union Medical College Hospital · 北京
- Peking University First Hospital · 北京
- Beijing Tongren Hospital CMU · 北京
- The First Hospital of Jilin University · 长春
- The Second Xiangya Hospital of Central South Hospital · 长沙
- Changzhou No 2 Peoples Hospital · 常州
- Beijing Chaoyang Hospital · 朝阳区
- Sichuan Provincial Peoples Hospital · 成都
- Chongqing University Cancer Hospital · 重庆
- Fujian Meidical University Union Hospital · 福州
- Nanfang Hospital · 广州
- Sun Yat -Sen University Cancer Center · 广州
- No.1 Affiliated Hospital, Medical College of Zhejiang University · 杭州
- The Second Affiliated Hospital of Zhejiang University · 杭州
- Harbin medical university cancer hospital · 哈尔滨
- Qilu Hospital of Shandong University · 济南
- The First Affliated Hospital Of Nanchang University · 南昌
- Nanjing Drum Tower Hospital · 南京
- Zhongda Hospital Southeast University · 南京
- The First Affiliated Hospital of Guangxi Medical University · 南宁
- Ruijin Hospital Shanghai Jiao Tong University · 上海
- Renji Hospital, Shanghai Jiaotong University School of Medicine · 上海
- Shanghai Fourth People s Hospital · 上海
- Shengjing Hospital Of China Medical University · 沈阳
- Peking University Shenzhen Hospital · 深圳
- Tianjin Medical University Cancer Institute and Hospital · 天津
- Institute of Hematology and Blood Diseases Hospital · 天津
- The First Affiliated Hospital of Wenzhou Medical University · 温州
- Wuhan Tongji Hospital Tongji Medical College · 武汉
- The Second Affiliated Hospital of Xi'an Jiaotong University · 西安
- The first affiliated hospital of xiamen university · 厦门
- Henan Cancer Hospital · 郑州
公开的入选条件
- * Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria
- * Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on to
- * Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
- * A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
- * A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the last dose of study treatment
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05552222；登记信息更新于 2026-09-25。